Replies to post #133088 on NorthWest Biotherapeutics Inc (NWBO)

[Astavakra]

I'm guessing the answer is No. This is a fantastic paper!

[Extremist223]

I recently had to reformat my computer and so I lost the old protocol for this trial (020221). If someone could post that again, I would be very grateful. I don't have the capacity to search the posts as I'm not a paid member of IHUB. However, the old protocol said that immune modulating concomitant medications are not allowed prior to crossover, which leaves the door open. We have discussed this a lot and I believe that anti-pd1 could have been used in this trial after crossover. In this prior discussion, right to try legislation, and physicians best judgement were integral. The three patients outlined in the abstract I'm not sure where they came from.

It just makes sense to me that some patients have received DCVAX + CI because anyone forward thinking enough to get into a clinical trial probably researched their hearts out and noticed anti-pd1's relevance to dcvax.

[abeta]

Was anyone on this board aware that combo treatment of humans had already occurred?

Never dawned on me.

[Evaluate]

Also see this regarding

A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma

https://clinicaltrials.gov/ct2/show/NCT02852655?term=NCT02852655&rank=1
ClinicalTrials.gov Identifier: NCT02852655
Sponsor: Dana-Farber Cancer Institute
Collaborator: Merck Sharp & Dohme Corp.
Locations:
United States, California
University of California, Los Angeles Recruiting
Los Angeles, California, United States, 90095
Contact: Timothy Clouthesy, MD 310-825-5321 [e-mail]
University of California, San Francisco Recruiting
San Francisco, California, United States, 94143-0372
Contact: Jennifer Clarke, MD 415-353-2966 [e-mail]
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Isabel Arrillaga-Romany, MD 617-724-8770 [e-mail]
Principal Investigator: Isabel Arrillaga-Romany, MD
Dana Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02115
Contact: Patrick Wen, MD 617-632-2166 [e-mail]
Principal Investigator: Patrick Wen, MD
United States, New York
Memorial Sloan-Kettering Cancer Recruiting
New York, New York, United States, 10065
Contact: Thomas Kaley, MD 212-639-5122 [e-mail]
United States, Texas
UT, MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: John de Groot, MD 713-745-3072 [e-mail]
United States, Utah
Huntsman Cancer Institute Recruiting
Salt Lake City, Utah, United States, 84112
Contact: Howard Colman, MD 801-587-4042 [e-mail]

[wavelengthy]

I'll note here (as others have before) that a Merck director speaks about Combination therapies immediately after Northwest's Linda Powers speaks about DcVax at the upcoming vaccines conference (sponsored by Northwest) late September...

[Doc logic]

biotrade49,

A while back Pyrrhonian posted a chart put together by a big pharma that demonstrated combo benefit between DC treatment and a checkpoint inhibitor. Mouse models also showed this to be true and I suggested in one of my posts to AVII77 that checkpoint inhibitors might be being tested at the crossover as a cheap way to verify synergy amongst a small group of patients before investing in any formal trial. He suggested the use of Avastin might be the more likely choice. This document indicates both were utilized and since there is no note about where these results came from it is fair to suppose they might belong to patients from the Phase 3 and or ancillary trials. The nGBM DCVax-L plus checkpoint inhibitor might have been patient choice leading to exclusion from the trial results or, perhaps more likely, screened but ineligible for the Phase 3 due to insufficient tumor for 5 vaccines. Best wishes.